Get started
TG Therapeutics, Inc.TG Therapeutics, Inc.TG Therapeutics, Inc.

TG Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

TGTX chart


Full chart

TGTX upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪6.31 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
292.19
Basic EPS (TTM)
0.16 USD
Net income (FY)
‪23.38 M‬ USD
Revenue (FY)
‪329.00 M‬ USD
Shares float
‪141.43 M‬
Beta (1Y)
0.79

Employees


Employees (FY)
338
Change (1Y)
+74 +28.03%
Revenue / Employee (1Y)
‪973.38 K‬ USD
Net income / Employee (1Y)
‪69.18 K‬ USD

About TG Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Michael Sean Weiss
Website
tgtherapeutics.com
Headquarters
Morrisville
Founded
1993
FIGI
BBG000FVZQY1
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

TGTX news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as TGTX.

Frequently Asked Questions


The current price of TGTX is 39.86 USD — it has decreased by −2.11% in the past 24 hours. Watch TG Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange TG Therapeutics, Inc. stocks are traded under the ticker TGTX.
TGTX stock has fallen by −5.45% compared to the previous week, the month change is a 34.39% rise, over the last year TG Therapeutics, Inc. has showed a 156.17% increase.
We've gathered analysts' opinions on TG Therapeutics, Inc. future price: according to them, TGTX price has a max estimate of 55.00 USD and a min estimate of 10.00 USD. Watch TGTX chart and read a more detailed TG Therapeutics, Inc. stock forecast: see what analysts think of TG Therapeutics, Inc. and suggest that you do with its stocks.
TGTX reached its all-time high on Mar 14, 2000 with the price of 149,411.41 USD, and its all-time low was 0.96 USD and was reached on Dec 29, 2011. View more price dynamics on TGTX chart.
See other stocks reaching their highest and lowest prices.
TGTX stock is 4.59% volatile and has beta coefficient of 0.79. Track TG Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is TG Therapeutics, Inc. there?
Today TG Therapeutics, Inc. has the market capitalization of ‪6.31 B‬, it has increased by 9.35% over the last week.
Yes, you can track TG Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
TG Therapeutics, Inc. is going to release the next earnings report on May 6, 2025. Keep track of upcoming events with our Earnings Calendar.
TGTX earnings for the last quarter are 0.15 USD per share, whereas the estimation was 0.16 USD resulting in a −4.55% surprise. The estimated earnings for the next quarter are 0.16 USD per share. See more details about TG Therapeutics, Inc. earnings.
TG Therapeutics, Inc. revenue for the last quarter amounts to ‪108.19 M‬ USD, despite the estimated figure of ‪100.67 M‬ USD. In the next quarter, revenue is expected to reach ‪117.13 M‬ USD.
TGTX net income for the last quarter is ‪23.33 M‬ USD, while the quarter before that showed ‪3.88 M‬ USD of net income which accounts for 501.29% change. Track more TG Therapeutics, Inc. financial stats to get the full picture.
No, TGTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 28, 2025, the company has 338 employees. See our rating of the largest employees — is TG Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TG Therapeutics, Inc. EBITDA is ‪42.21 M‬ USD, and current EBITDA margin is 12.83%. See more stats in TG Therapeutics, Inc. financial statements.
Like other stocks, TGTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TG Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TG Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TG Therapeutics, Inc. stock shows the buy signal. See more of TG Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.